Skip to main content

Research News

Pharma Courses
  • ‘Crowd and Mask’ Monitoring System to prevent COVID-19

    Innovators at Indian Institute of Science Education and Research (IISER), Bhopal have developed a unique ‘Crowd and Mask’ Monitoring System to prevent COVID-19 from spread. This one-of-its-kind low cost Artificial Intelligence (AI)-enabled device is portable and easy to deploy across various locations, says a statement released by the institution.

  • Novel technique may help in early detection of Cancer, Alzheimer’s, and Parkinson’s

    Scientists from Raman Research Institute (RRI) have developed a new technique to measure DNA modifications that can have applications in the early diagnosis of multiple diseases like Cancer, Alzheimer’s, and Parkinson’s diseases.

  • Neurologists Identify Consistent Neuroinflammatory Response in ICH Patients

    Understanding how the immune system responds to acute brain hemorrhage could open doors to identifying treatments for this devastating disease. However, up until now, there has been limited information on inflammation in the brain from human patients, especially during the first days after a hemorrhagic stroke.

    This led a team of researchers to partner with a large clinical trial of minimally-invasive surgery to tackle defining the human neuroinflammatory response in living patients.

  • New potential drug to treat SARS-CoV-2

    A federally approved heart medication shows significant effectiveness in interfering with SARS-CoV-2 entry into the human cell host, according to a new study by a research team from Texas A&M University and The University of Texas Medical Branch (UTMB).

    The medication bepridil, which goes by the trade name Vascor, is currently approved by the U.S. Food and Drug Administration (FDA) to treat angina, a heart condition.

  • New potential therapy for Crohn's disease in children

    Scientists from the Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago demonstrated that a nanotherapy reduces intestinal inflammation and shrinks lesions in a rodent model of severe Crohn's disease. This approach could become an alternative to biologic antibody therapies that carry many side effects, including increased risk of certain cancers. It might also prevent the need for surgery in the future. Findings were published in the journal Advanced Therapeutics.

  • A machine-learning approach to finding treatment options for Covid-19

    When the Covid-19 pandemic struck in early 2020, doctors and researchers rushed to find effective treatments. There was little time to spare. "Making new drugs takes forever," says Caroline Uhler, a computational biologist in MIT's Department of Electrical Engineering and Computer Science and the Institute for Data, Systems and Society, and an associate member of the Broad Institute of MIT and Harvard. "Really, the only expedient option is to repurpose existing drugs."

  • Aspirin preferred to prevent blood clots in kids after heart surgery : Research

    Aspirin should be favoured over warfarin to prevent blood clotting in children who undergo a surgery that replumbs their hearts, according to a new study.

    The research, led by the Murdoch Children’s Research Institute (MCRI) and published in The Journal of Thoracic and Cardiovascular Surgery, will have implications for clinicians when prescribing blood thinning medications after Fontan surgery, a complex congenital heart disease operation redirecting blood flow from the lower body to the lungs.

  • Green Tea Compound Aids Tumor-Suppressing, DNA-Repairing Protein : Research

    An antioxidant found in green tea may increase levels of p53, a natural anti-cancer protein, known as the “guardian of the genome” for its ability to repair DNA damage or destroy cancerous cells. Published today in Nature Communications, a study of the direct interaction between p53 and the green tea compound, epigallocatechin gallate (EGCG), points to a new target for cancer drug discovery.

  • Immunotherapy – targeted drug combination improves survival in advanced kidney cancer

    Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.

  • New synthetic peptides could attenuate atherosclerosis : Research

    Research over the last 20 years has shown that atherosclerosis is a chronic inflammatory condition of the arterial blood vessel wall. Soluble mediators such as cytokines and chemokines are pivotal players in this disease, promoting vascular inflammation. However, the development of anti-inflammatory therapeutics directed against such mediators that could prevent atherosclerosis has proven difficult, despite promising clinical studies in the recent past.

Subscribe to Research News